RENA THERAPEUTICS
In the pharmaceutical market, attention has been focused on nucleic acid drugs to meet unmet medical needs such as cancer and intractable diseases.This is because nucleic acid drugs have the following advantages.It is possible to target intracellular drug molecules that could not be targeted by conventional drugsDrug discovery research is possible for any gene as long as there is technology to deliver nucleic acids to the expression siteMore specific than low molecular weight compounds and less susceptible to side effects Unlike antibody drugs, nucleic acid drugs can be manufactured by chemical synthesis at a relatively low cost.
RENA THERAPEUTICS
Industry:
Biotechnology Clinical Trials Health Care Health Diagnostics Manufacturing Pharmaceutical
Founded:
2015-01-15
Address:
Tokyo, Tokyo, Japan
Country:
Japan
Website Url:
http://www.renatherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
03-4243-6081
Total Funding:
10.16 M USD
Technology used in webpage:
Viewport Meta SPF SSL By Default Google Font API Google Analytics LetsEncrypt WordPress Google Universal Analytics Font Awesome Wordpress Plugins
Similar Organizations
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Current Advisors List
Current Employees Featured
Founder
Investors List
KSP
KSP investment in Venture Round - Rena Therapeutics
Innovation Network Corporation of Japan
Innovation Network Corporation of Japan investment in Venture Round - Rena Therapeutics
Nippon Shokubai
Nippon Shokubai investment in Venture Round - Rena Therapeutics
Innovation Network Corporation of Japan
Innovation Network Corporation of Japan investment in Venture Round - Rena Therapeutics
Innovation Network Corporation of Japan
Innovation Network Corporation of Japan investment in Series A - Rena Therapeutics
KSP
KSP investment in Series A - Rena Therapeutics
DBJ Capital
DBJ Capital investment in Series A - Rena Therapeutics
Official Site Inspections
http://www.renatherapeutics.com
- Host name: 183.181.98.219
- IP address: 183.181.98.219
- Location: Osaka Japan
- Latitude: 34.6848
- Longitude: 135.5142
- Timezone: Asia/Tokyo
- Postal: 543-0062
More informations about "Rena Therapeutics"
レナセラピューティクス株式会社│Rena Therapeutics Inc.
レナセラピューティクス株式会社は、横田隆徳教授らにより開発されたヘテロ核酸技術を第3のプラットフォーム技術として確立し、新しい核酸医薬品の創製を目的とした東京医科歯科大 …See details»
COMPANY│レナセラピューティクス株式会社
Company Name: Rena Therapeutics Inc. Address: Global Business Hub Tokyo, Otemachi Finacial City Ground Cube 3F 9-2, Otemachi 1-chome, Chiyoda-ku, Tokyo 100-0004See details»
レナセラピューティクス株式会社│Rena Therapeutics Inc.
レナセラピューティクス株式会社は、横田隆徳教授らにより開発されたヘテロ核酸技術を第3のプラットフォーム技術として確立し、新しい核酸医薬品の創製を目的とした東京医科歯科大 …See details»
Rena Therapeutics Company Profile | Management and Employees …
Rena Therapeutics Co., Ltd. was established in January 2015, aimed to accelerate Hetero Duplex Oligonucleotide (HDO) technology, an epoch - making nucleic acid technology for drug …See details»
Rena Therapeutics Company Profile 2024: Valuation, …
Information on acquisition, funding, cap tables, investors, and executives for Rena Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Rena Therapeutics Inc. | INCJ, Ltd.
Jun 30, 2017 · Support a biotech company to commercialize a platform technology to strengthen nucleic acid therapeutics research in Japan; Maximize value of intellectual properties …See details»
Rena Therapeutics Inc. / レナセラピューティクス株式会社 | LinkedIn
Rena Therapeutics Inc. / レナセラピューティクス株式会社 | 35 followers on LinkedIn. Rena Therapeutics Inc. was established in January 2015 with the aim of accelerating the practical …See details»
Nippon Shokubai Acquires the Ownership of Rena Therapeutics
Evaluated the high possibility of HDO technology, Rena Therapeutics executed non-exclusive license agreements with Ionis Pharmaceuticals, Inc. which is global leading company in RNA …See details»
Rena Therapeutics - Overview, News & Similar companies
View Rena Therapeutics (www.renatherapeutics.com) location in Ibaraki, Japan , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
Nippon Shokubai Announces Signing of License Agreement with …
About Rena Therapeutics: Rena Therapeutics is a venture company authorized by Tokyo Medical and Dental University (TMDU) in order to accelerate the Heteroduplex Oligonucleotide (HDO) …See details»
Rena Therapeutics - Products, Competitors, Financials, Employees ...
Rena Therapeutics is a venture company authorized by Tokyo Medical and Dental University (TMDU) in order to accelerate the Hetero Duplex Oligonucleotide (HDO) technology and drive …See details»
ABOUT - レナセラピューティクス株式会社│Rena ...
企業情報 : レナセラピューティクス株式会社は、横田隆徳教授らにより開発されたヘテロ核酸技術を第3のプラットフォーム技術として確立し、新しい核酸医薬品の創製を目的とした東京 …See details»
Rena Therapeutics - Crunchbase Company Profile & Funding
In the pharmaceutical market, attention has been focused on nucleic acid drugs to meet unmet medical needs such as cancer and intractable diseases.This is because nucleic acid drugs …See details»
つながりの輪で核酸医薬に革新を起こす｜レナセラピューティク …
レナセラピューティクス株式会社は、横田隆徳教授らにより開発されたヘテロ核酸技術を第3のプラットフォーム技術として確立し、新しい核酸医薬品の創製を目的とした東京医科歯科大 …See details»
レナセラピューティクス株式会社 | 株式会社INCJ
株式会社incjは、産業や組織の壁を超えた“オープンイノベーション”を活用し、新たな付加価値を創出する革新性を有する事業に対して成長資金を提供し経営参加型の支援を行いますSee details»
Rena Therapeutics - Craft
See insights on Rena Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
会社概要│レナセラピューティクス株式会社
会社概要 : レナセラピューティクス株式会社は、横田隆徳教授らにより開発されたヘテロ核酸技術を第3のプラットフォーム技術として確立し、新しい核酸医薬品の創製を目的とした東京 …See details»
Rena Therapeutics - VentureRadar
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous …See details»
DNA/RNA heteroduplex oligonucleotide (HDO) a platform …
DNA/RNA heteroduplex oligonucleotide (HDO) is the third platform technology for mRNA Therapy following short interfering RNA (siRNA) and single-stranded DNA (ASO), which serves as a …See details»
日本触媒グループへの参画のお知らせ - renatherapeutics.com
日本触媒グループへの参画のお知らせ : レナセラピューティクス株式会社は、横田隆徳教授らにより開発されたヘテロ核酸技術を第3のプラットフォーム技術として確立し、新しい核酸医 …See details»